---
title: "Eton Pharmaceuticals, Inc. (ETON.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ETON.US.md"
symbol: "ETON.US"
name: "Eton Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-04-15T15:34:42.041Z"
locales:
  - [en](https://longbridge.com/en/quote/ETON.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ETON.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ETON.US.md)
---

# Eton Pharmaceuticals, Inc. (ETON.US)

## Company Overview

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.etonpharma.com](https://www.etonpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:17.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 72 / 187 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 104.94% |  |
| Net Profit YoY | -20.35% |  |
| P/B Ratio | 28.29 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 739955395.92 |  |
| Revenue | 79950000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -18.19% | E |
| Profit Margin | -5.75% | D |
| Gross Margin | 59.83% | B |
| Revenue YoY | 104.94% | A |
| Net Profit YoY | -20.35% | D |
| Total Assets YoY | 21.01% | A |
| Net Assets YoY | 7.07% | B |
| Cash Flow Margin | -228.73% | E |
| OCF YoY | 104.94% | A |
| Turnover | 0.95 | A |
| Gearing Ratio | 71.61% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Eton Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "104.94%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "28.29",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "739955395.92",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "79950000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-18.19%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-5.75%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "59.83%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "104.94%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.35%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.01%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.07%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-228.73%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "104.94%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.95",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "71.61%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -160.82 | 229/187 | - | - | - |
| PB | 28.29 | 188/187 | 21.13 | 19.34 | 17.23 |
| PS (TTM) | 9.26 | 114/187 | 9.19 | 7.98 | 6.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-20T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 26.89 |
| Highest Target | 52.00 |
| Lowest Target | 31.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ETON.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ETON.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ETON.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ETON.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**